| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
98,530,000 |
| Market
Cap: |
18.88(M) |
| Last
Volume: |
78,874 |
Avg
Vol: |
78,656 |
| 52
Week Range: |
$0.1916 - $0.1916 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Abeona Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Co.'s primary clinical program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, which is in the pivotal Phase 3 VIITAL™ clinical trial. Co. is developing additional adeno-associated virus (AAV)-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM™ capsid platform that Co. has licensed from University of North Carolina at Chapel Hill, and internal AAV vector research programs.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
31,758 |
51,758 |
77,758 |
93,627 |
| Total Buy Value |
$102,237 |
$190,037 |
$294,295 |
$352,590 |
| Total People Bought |
4 |
4 |
4 |
4 |
| Total Buy Transactions |
4 |
5 |
8 |
11 |
| Total Shares Sold |
0 |
7,084 |
41,479 |
98,636 |
| Total Sell Value |
$0 |
$36,199 |
$179,159 |
$193,613 |
| Total People Sold |
0 |
1 |
5 |
5 |
| Total Sell Transactions |
0 |
1 |
8 |
13 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Charles Faith L. |
Director |
– • – |
2022-09-26 |
4 |
A |
$0.00 |
$0 |
D/D |
13,400 |
20,414 |
|
- |
|
| Wuchterl Donald A. |
Director |
– • – |
2022-09-26 |
4 |
A |
$0.00 |
$0 |
D/D |
13,400 |
20,414 |
|
- |
|
| Wider Todd |
Director |
– • – |
2022-09-26 |
4 |
A |
$0.00 |
$0 |
D/D |
13,400 |
16,907 |
|
- |
|
| Amoroso Michael |
Director |
– • – |
2022-09-26 |
4 |
A |
$0.00 |
$0 |
D/D |
13,400 |
57,711 |
|
- |
|
| Alvino Mark |
Director |
– • – |
2022-09-26 |
4 |
A |
$0.00 |
$0 |
D/D |
13,400 |
18,414 |
|
- |
|
| Silverstein Christine Berni |
Director |
– • – |
2022-09-26 |
4 |
A |
$0.00 |
$0 |
D/D |
13,400 |
35,525 |
|
- |
|
| Omalley Brendan M. |
SVP, General Counsel |
• – – |
2022-09-21 |
4 |
D |
$3.72 |
$1,782 |
D/D |
(479) |
9,071 |
|
- |
|
| Vazzano Joseph Walter |
Chief Financial Officer |
• – – |
2022-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
20,000 |
|
- |
|
| Alvino Mark |
Director |
– • – |
2022-06-15 |
4 |
S |
$0.15 |
$3,098 |
D/D |
(20,000) |
27,181 |
|
100% |
|
| Alvino Mark |
Director |
– • – |
2022-06-06 |
4 |
S |
$0.16 |
$5,464 |
D/D |
(35,000) |
47,181 |
|
100% |
|
| Seshadri Vishwas |
Chief Executive Officer |
• • – |
2022-06-01 |
4 |
D |
$0.16 |
$13,044 |
D/D |
(81,525) |
268,475 |
|
- |
|
| Vazzano Joseph Walter |
Chief Financial Officer |
• – – |
2022-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
200,000 |
|
- |
|
| Omalley Brendan M. |
SVP, General Counsel |
• – – |
2021-12-06 |
4 |
AS |
$0.57 |
$5,035 |
D/D |
(8,880) |
204,750 |
|
-55% |
|
| Omalley Brendan M. |
SVP, General Counsel |
• – – |
2021-11-05 |
4 |
AS |
$0.89 |
$7,894 |
D/D |
(8,880) |
213,630 |
|
-68% |
|
| Seshadri Vishwas |
Chief Executive Officer |
• • – |
2021-10-15 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
350,000 |
|
- |
|
| Omalley Brendan M. |
SVP, General Counsel |
• – – |
2021-10-11 |
4 |
AS |
$0.90 |
$23,271 |
D/D |
(25,734) |
222,510 |
|
-74% |
|
| Omalley Brendan M. |
SVP, General Counsel |
• – – |
2021-10-08 |
4 |
AS |
$1.05 |
$23,915 |
D/D |
(22,763) |
248,244 |
|
-75% |
|
| Carr Edward |
Chief Financial Officer |
• – – |
2021-10-08 |
4 |
AS |
$1.05 |
$30,596 |
D/D |
(29,122) |
400,169 |
|
-75% |
|
| Wider Todd |
Director |
– • – |
2021-10-07 |
4 |
S |
$0.97 |
$24,150 |
D/D |
(25,000) |
0 |
|
74% |
|
| Omalley Brendan M. |
SVP, General Counsel |
• – – |
2021-10-05 |
4 |
AS |
$1.05 |
$2,569 |
D/D |
(2,447) |
271,007 |
|
-72% |
|
| Amoroso Michael |
Chief Executive Officer |
• • – |
2021-09-30 |
4 |
AS |
$1.09 |
$49,382 |
D/D |
(45,409) |
604,637 |
|
-76% |
|
| Omalley Brendan M. |
SVP, General CounselOfficer |
• – – |
2021-09-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
137,454 |
|
-79% |
|
| Omalley Brendan M. |
SVP, General Counsel |
• – – |
2021-09-20 |
4 |
A |
$0.00 |
$0 |
D/D |
136,000 |
273,454 |
|
- |
|
| Carr Edward |
Chief Financial Officer |
• – – |
2021-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
238,000 |
429,291 |
|
- |
|
| Seshadri Vishwas |
SVP, Head of Res./Clin. Dev. |
• – – |
2021-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
300,000 |
300,000 |
|
- |
|
156 Records found
|
|
Page 3 of 7 |
|
|
